当前蛋白身份:Q15561 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
5GZB Crystal Structure of Transcription Factor TEAD4 in Complex with M-CAT DNA 提交 2016-09-28 Assembly 1 蛋白–DNA 单体;蛋白 × 1 PDB 声明:trimeric(3) 与全部聚合物一致
链 A 36–139(104 aa) 片段:UNP residues 36-139
非标准单体:是(mmCIF未提供具体位点) GOL GLYCEROL × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;0.6 M Na2HPO4, 0.6 M KH2PO4, 0.1 M HEPES
分辨率 2.70 Å R-free 0.256
5NO6 TEAD4-HOXB13 complex bound to DNA 提交 2017-04-11 Assembly 1 蛋白–DNA 异源复合物;蛋白 × 2 PDB 声明:tetrameric(4) 与全部聚合物一致
链 N 40–112(73 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.24;298 K;PEG (4000), Ammonium sulphate, PME(550, MOPs
分辨率 2.88 Å R-free 0.317
5NO6 TEAD4-HOXB13 complex bound to DNA 提交 2017-04-11 Assembly 2 蛋白–DNA 异源复合物;蛋白 × 2 PDB 声明:tetrameric(4) 与全部聚合物一致
链 I 40–112(73 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.24;298 K;PEG (4000), Ammonium sulphate, PME(550, MOPs
分辨率 2.88 Å R-free 0.317
5OAQ TEAD4 COMPLEXED WITH YAP PEPTIDE AND MYRISTATE (COVALENTLY BOUND) 提交 2017-06-23 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 217–434(218 aa) 片段:C-terminal domain, YAP binding domain
未记录 GOL GLYCEROL × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6;298 K;15% PEG 3350,2% tacsimate, 0.1M NaCitrate
分辨率 1.95 Å R-free 0.252
6GE3 X-ray structure of TEAD4 (wildtype) complexed with YAP (wildtype): The role of residual flexibility and water molecules in the adaptation of a bound intrinsically disordered protein to mutations at a binding interface 提交 2018-04-25 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 216–434(219 aa) 片段:C-terminal domain, YAP binding domain
未记录 MYR MYRISTIC ACID × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6;298 K;16% PEG 3350,2% tacsimate, 0.1M NaCit, pH 5.6
分辨率 1.85 Å R-free 0.242
6GE4 TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 1.97A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA 提交 2018-04-25 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 216–434(219 aa) 片段:C-terminal domain, YAP binding domain
未记录 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;298 K;20% PEG 3350, 0.2M MgNitrate
分辨率 1.97 Å R-free 0.241
6GE5 TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.05A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA 提交 2018-04-25 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 216–434(219 aa) 片段:C-terminal domain, YAP binding domain
未记录 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 4;298 K;20% PEG 3350, 8% Tacsimate
分辨率 2.05 Å R-free 0.238
6GE6 X-ray structure of TEAD4(E263A+Y429F mutant) complexed with YAP(wildtype): The role of residual flexibility and water molecules in the adaptation of a bound intrinsically disordered protein to mutations at a binding interface 提交 2018-04-25 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 173–391(219 aa) 片段:C-terminal domain, YAP binding domain
未记录 MYR MYRISTIC ACID × 1 PO4 PHOSPHATE ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.5;298 K;2M ammonium sulfate, 0.1M Bis-TRIS
分辨率 1.80 Å R-free 0.238
6GEC TEAD4 (216-434) COMPLEXED WITH YAP PEPTIDE (60-100);S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.70A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA 提交 2018-04-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 216–434(219 aa) 片段:C-terminal domain, YAP binding domain
未记录 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;298 K;20% PEG 3350, 0.2M NaTartrate
分辨率 1.70 Å R-free 0.242
6GEE TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.96A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA 提交 2018-04-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 216–434(219 aa) 片段:C-terminal domain, YAP binding domain
突变:E263A MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.5;298 K;17% PEG 10000, 0.1M ammonium acetate, 0.1M Bis-TRIS
分辨率 1.96 Å R-free 0.245
6GEG TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 2.23A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA 提交 2018-04-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 216–434(219 aa) 片段:C-terminal domain, YAP binding domain
突变:Y429F MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;298 K;20% PEG 3350, 0.2M Na tartrate
分辨率 2.23 Å R-free 0.236
6GEI TEAD4 (216-434);E263A+Y429F COMPLEXED WITH YAP PEPTIDE (60- 100);S94A AND MYRISTOATE (COVALENTLY BOUND TO LYS344, NOT CYS367!) AT 1.65A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA 提交 2018-04-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 216–434(219 aa) 片段:C-terminal domain, YAP binding domain
突变:E263A+Y429F MYR MYRISTIC ACID × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;20% PEG 3350, 0.2M Na acetate
分辨率 1.65 Å R-free 0.248
6GEK TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.28A (P212121 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA 提交 2018-04-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 216–434(219 aa) 片段:C-terminal domain, YAP binding domain
突变:Y429F MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.5;298 K;25% PEG 3350, 0.2M MgCl2, 0.1M Bis-TRIS
分辨率 2.28 Å R-free 0.246
6GEK TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.28A (P212121 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA 提交 2018-04-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 216–434(219 aa) 片段:C-terminal domain, YAP binding domain
突变:Y429F MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.5;298 K;25% PEG 3350, 0.2M MgCl2, 0.1M Bis-TRIS
分辨率 2.28 Å R-free 0.246
6HIK X-ray structure of TEAD4(Y429H) mutant) complexed with YAP (wildtype): Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy 提交 2018-08-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 173–391(219 aa) 片段:C-terminal domain, YAP binding domain
未记录 MYR MYRISTIC ACID × 1 PO4 PHOSPHATE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;298 K;1.4M Na/K PO4
分辨率 1.65 Å R-free 0.237
6Q2X TEAD4 (216-434) COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.1A (P41212 CRYSTAL FORM) 提交 2018-12-03 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 217–434(218 aa) 片段:C-terminal domain, YAP binding domain
未记录 GOL GLYCEROL × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;298 K;16% PEG 3350,2% tacsimate, 0.1M NaCit
分辨率 2.10 Å R-free 0.253
6Q36 TEAD4(216-434) complexed with optimized peptide 9 and myristoate (covalently bound) at 2.01A resolution: Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence 提交 2018-12-03 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 217–434(218 aa) 片段:C-terminal domain, YAP binding domain
链 B 217–434(218 aa) 片段:C-terminal domain, YAP binding domain
未记录 MYR MYRISTIC ACID × 2 PO4 PHOSPHATE ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;298 K;0.9 M NaK Phosphate
分辨率 2.01 Å R-free 0.244
6SEN TEAD4 bound to a FAM181A peptide 提交 2019-07-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 217–434(218 aa)
非标准单体:是(mmCIF未提供具体位点) SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 4.59;293 K;200 mM Ammonium sulfate 100 mM Sodium acetate trihydrate pH 4.59 35% Pentaerythritol ethoxylate (15/4 EO/OH)
分辨率 1.65 Å R-free 0.219
6SEN TEAD4 bound to a FAM181A peptide 提交 2019-07-30 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 217–434(218 aa)
非标准单体:是(mmCIF未提供具体位点) SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 4.59;293 K;200 mM Ammonium sulfate 100 mM Sodium acetate trihydrate pH 4.59 35% Pentaerythritol ethoxylate (15/4 EO/OH)
分辨率 1.65 Å R-free 0.219
6SEO TEAD4 bound to a FAM181B peptide 提交 2019-07-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 174–391(218 aa)
非标准单体:是(mmCIF未提供具体位点) 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;50 mM ammonium sulfate 50 mM Bis-TRIS pH 6.5 30% Pentaerythritol ethoxylate (15/4 EO/OH)
分辨率 2.55 Å R-free 0.232
8A8R Crystal structure of TEAD4 in complex with YAP peptide 提交 2022-06-23 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 216–434(219 aa) 片段:C-terminal domain, YAP binding domain
链 B 216–434(219 aa) 片段:C-terminal domain, YAP binding domain
未记录 MYR MYRISTIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;50 mM sodium acetate trihydrate pH 4.6 50 mM magnesium acetate tetrahydrate 25% PEG400
分辨率 1.70 Å R-free 0.243
8C17 Crystal structure of TEAD4 in complex with peptide 1 提交 2022-12-20 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 217–434(218 aa)
未记录 GOL GLYCEROL × 4 MYR MYRISTIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;2.4 M sodium malonate
分辨率 2.25 Å R-free 0.238
8CAA Crystal structure of TEAD4 in complex with YTP-13 提交 2023-01-24 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 217–434(218 aa) 片段:C-terminal domain, YAP binding domain
链 B 217–434(218 aa) 片段:C-terminal domain, YAP binding domain
未记录 U3F 4-[bis(fluoranyl)methoxy]-2-[(2~{S})-5-chloranyl-6-fluoranyl-2-[[(4-oxidanylcyclohexyl)amino]methyl]-2-phenyl-3~{H}-1-benzofuran-4-yl]-3-fluoranyl-benzamide × 2 U3O (2~{R})-2-[2-chloranyl-5-[2-chloranyl-4-(trifluoromethyl)phenoxy]phenyl]sulfanylpropanoic acid × 2 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;22% PEG 3350 (w/v) , 0.25 M ammonium citrate dibasic
分辨率 2.00 Å R-free 0.237
9QKQ Crystal structure of hTEAD4 YAP binding domain (hTEAD4-YBD) in complex with peptide 6 提交 2025-03-20 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 217–434(218 aa)
未记录 EDO 1,2-ETHANEDIOL × 9 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;0.9-1.2 M sodium/potassium phosphate buffer at pH 5.6
分辨率 1.74 Å R-free 0.221
9QKQ Crystal structure of hTEAD4 YAP binding domain (hTEAD4-YBD) in complex with peptide 6 提交 2025-03-20 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 217–434(218 aa)
未记录 EDO 1,2-ETHANEDIOL × 1 MYR MYRISTIC ACID × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;0.9-1.2 M sodium/potassium phosphate buffer at pH 5.6
分辨率 1.74 Å R-free 0.221
9SYI Crystal structure of TEAD4 in complex with compound 9 提交 2025-10-13 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 217–434(218 aa)
链 B 217–434(218 aa)
未记录 U3O (2~{R})-2-[2-chloranyl-5-[2-chloranyl-4-(trifluoromethyl)phenoxy]phenyl]sulfanylpropanoic acid × 2 A1ICN 2-[(2~{S})-5-chloranyl-2-phenyl-2-[(2~{S})-pyrrolidin-2-yl]-3~{H}-1-benzofuran-4-yl]-3-fluoranyl-4-methoxy-benzamide × 2 PO4 PHOSPHATE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;sodium/potassium phosphate
分辨率 2.10 Å R-free 0.245
9SYN Crystal structure of TEAD4 in complex with Vgll1-peptide and IAG933 提交 2025-10-13 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 217–434(218 aa)
未记录 MYR MYRISTIC ACID × 1 WCF 4-[(2~{S})-5-chloranyl-6-fluoranyl-2-phenyl-2-[(2~{S})-pyrrolidin-2-yl]-3~{H}-1-benzofuran-4-yl]-5-fluoranyl-6-(2-hydroxyethyloxy)-~{N}-methyl-pyridine-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;Ammonium sulfate, HEPES, PEG3350
分辨率 1.30 Å R-free 0.233